Frontier Biotech's De Facto Controlling Shareholder, Representative Director Lee Tae-hoon, Increases Shareholding by 92,000 Shares... Ownership Ratio Rises by 1.02 Percentage Points

Frontier Biotech (110020) reported that its de facto controlling shareholder, Representative Director Lee Tae-hoon, increased his shareholding by 92,000 shares, raising his ownership stake from 4.44% to 5.46%. The stock price closed at 1,800 won on July 28, down 6.88% from the previous day. As of December 2025's settlement, the company reported assets of 185 billion won, liabilities of 11 billion won, equity of 174 billion won, revenue of 137 billion won, an operating loss of 3 billion won, and a net loss of 2 billion won. Listed on KOSDAQ since December 2018, the company operates in the miscellaneous chemical products manufacturing industry.